Her2 Expression Current Events | Her2 Expression News
|
| Page
1 of
26 |
513 Results |
|
|
|
Sort By:
Page Views | Date |
Which is promising as therapeutic targets in patients with biliary tract cancer? EGFR or HER2?
The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. view more (2009-10-16)
HER2 levels may aid in treatment selection for metastatic breast cancer
Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. view more (2008-12-03)
Study shows PET can measure effectiveness of novel breast cancer treatment
A new study published in the July issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) scans in mice can be used to determine whether a novel type of breast cancer treatment is working as intended. view more (2009-07-02)
Translational derepression & oncogene expression in breast cancer cells
Drs. Anuradha Mehta, Christopher Trotta and Stuart Peltz (PTC Therapeutics) have uncovered a novel mechanism whereby the translation efficiency of oncogenes is increased in cancer cells. view more (2006-03-31)
Herceptin gives disappointing results in lung cancer trial
Trastuzumab (Herceptin) - a treatment that has increased survival in many breast cancer patients - has failed to live up to hopes that it might also help lung cancer patients. view more (2004-01-08)
UC Davis researchers discover a key to aggressive breast cancer
In trying to find out why HER2-positive breast cancer can be more aggressive than other forms of the disease, UC Davis Cancer Center researchers have surprisingly discovered that HER2 itself is the culprit. By shutting down its own regulator gene, HER2 creates a permissive environment for tumor growth. view more (2008-10-31)
Anthracyclines improve survival in HER2-positive breast cancer patients
Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors. view more (2007-12-26)
Protein predicts development of invasive breast cancer in women with DCIS, Penn study shows
Women with ductal carcinoma in situ (DCIS) who exhibit an overexpression of the protein HER2/neu have a six-fold increase in risk of invasive breast cancer. view more (2009-05-22)
Gene patenting -- steep cost for health care and patients
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25% of all breast cancers). view more (2007-05-08)
Information about the use and accuracy of breast cancer tests is lacking, study finds
A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin). view more (2009-09-14)
NIST, NCI, SAIC partner on new method for detecting HER2 breast cancer
Generations of mothers have served up chicken soup to remedy the common cold, but now the therapeutic fowl may find use in diagnosis as well. Researchers at the National Institute of Standards and Technology (NIST), the National Cancer Institute (NCI) and the scientific research firm SAIC recently showed how chicken antibodies may one day improve... view more... (2008-02-20)
Patient outcomes linked to biomarker levels by quantitative technology
Researchers in the Department of Pathology at Yale University School of Medicine report that when using current pathology methods of biomarker detection, the concentration of antibodies used dramatically alters the apparent relationship of biomarker level to clinical outcome. view more (2005-12-21)
Breast cancer subtypes linked to survival from secondary brain tumors
Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases. view more (2008-02-28)
Researchers call for wider implementation of FISH testing in metastatic breast cancer
Accurate diagnostic assessment of HER2 is essential for the effective treatment of metastatic breast cancer. Results to be published in the April issue of the Journal of Pathology indicate that FISH testing has many advantages over other methods, however in the UK there are very few diagnostic laboratories with the expertise to carry out the test.... view more... (2003-02-26)
New Herceptin results confirm impressive reduction in risk of cancer returning
New Herceptin results confirm impressive reduction in risk of cancer returning in women with aggressive form of early-stage breast cancer. view more (2005-09-14)
Light reveals breast tumor oxygen status
Light directed at a breast tumor through a needle can provide pathologists with biological specifics of the tumor and help oncologists choose treatment options that would be most effective for that individual patient. view more (2009-04-01)
M. D. Anderson study finds change in HER2 status after treatment with Herceptin
Researchers at The University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. view more (2008-09-04)
Vaccine against HER2-positive breast cancer offers complete protection in lab
Researchers at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 therapy - without any toxicity. view more (2008-09-15)
Breast cancer etiology may vary by subtype
Women's reproductive and lifestyle characteristics can be linked to different invasive breast cancer subtypes. Data on 2544 breast cancer cases, presented in the open access journal Breast Cancer Research, suggests that traditional risk factors for development of the condition are associated with different kinds of tumor. view more (2009-05-22)
Analysis confirms benefits of combining trastuzumab and chemotherapy
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer. view more (2007-07-09)
|
|
| Page
1 of
26 |
513 Results |
|
|
|
Sort By:
Page Views | Date |
|
